<DOC>
	<DOCNO>NCT00672295</DOCNO>
	<brief_summary>Primary objective determine maximal tolerate ( MTD ) dasatinib combination paclitaxel carboplatin first cycle treatment . Secondary objective describe toxicity combination therapy ; describe pharmacokinetics pharmacodynamics parameter related combination ; describe clinical activity define response rate ( complete partial response rate ) progression-free survival &gt; 6 month ; compare SRC pathway microarray signature pre post-treatment cancer specimen ; evaluate SRC pathway downstream substrate , FAX , paxcillin , CRK-L pre post-treatment cancer specimen .</brief_summary>
	<brief_title>PH I SRC Kinase , Dasatinib Combo Paclitaxel &amp; Carboplatin Pts w Ovarian , Peritoneal , &amp; Tubal Cancer</brief_title>
	<detailed_description>This phase I multicenter study design determine maximal tolerate dose ( MTD ) toxicity dasatinib combination paclitaxel carboplatin first cycle treatment patient advance recurrent ovarian , peritoneal , tubal carcinoma . The MTD define high dose 1 6 evaluable patient experience dose-limiting toxicity ( DLT ) due combination dasatinib , paclitaxel , carboplatin first cycle treatment .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Pts must histologic cytologic evidence ovarian , peritoneal , tubal cancer All pt must measurable disease &gt; 18 yr Expected survival least 3 month Pts must GOG performance status pf 0 , 1 2 Pts must adequate : Bone marrow function , renal function , hepatic function , neurologic function No chemo , radiotherapy , biologic , hormonal , investigational drug therapy within 28 day prior study entry Pts may 3 prior cytotoxic chemo regimens include prior treatment w carboplatin &amp; paclitaxel Capable provide write informed consent Pts childbearing potential must negative serum pregnancy test prior study entry &amp; practice effective method birth control course study , manner risk failure minimize . Prior study enrollment , woman childbearing potential must advise importance avoid pregnancy trial participation &amp; potential risk factor unintentional pregnancy Pts must tissue block tumor available evaluation microarray &amp; immunoblot analysis . Pretreatment tumor tissue may obtain either archival tissue obtain guide guide core needle simple biopsy must perform within four week prior enrollment study . Pts must tumor accessible biopsy &amp; consent undergo posttreatment biopsy cycle # 2 treatment well Pts w epithelial ovarian tumor low malignant potential ( borderline tumor ) Pts w history invasive malignancy , w exception nonmelanoma skin cancer , exclude evidence malignancy present within last 5 yrs Pts follow cardiac condition : uncontrolled angina myocardial infarction within past 6 month ; diagnose suspect congenital long QT syndrome ; Any history clinically significant ventricular arrhythmia ; Prolonged QTc interval preentry electrocardiogram Fridericia &amp; Bazett 's correction ; uncontrolled hypertension History significant bleeding disorder unrelated cancer , include : diagnosed congenital bleeding disorder ; diagnose acquire bleed disorder within 1 yr Pts currently take drug generally accept risk cause Torsades de Pointes include : quinidine , procainamide , disopyramide ; amiodarone , sotalol , ibutilide , dofetilide ; erythromycin , clarithromycin ; chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide ; cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine Serum creatinine &gt; 1.5 time institutional upper limit normal Pts take certain concomitant medication , consider follow prohibition : medication inhibit platelet function anticoagulant Pts receive radiation therapy &gt; 30 percent bone marrow Pts w history grade 3 hypersensitivity paclitaxel carboplatin Pts w septicemia , severe infection , acute hepatitis , uncontrolled severe medical condition</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Peritoneal Cancer</keyword>
	<keyword>Tubal Cancer</keyword>
	<keyword>Fallopian Tube Cancer</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>Sprycel</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
</DOC>